Summary
GBI Research, the leading business intelligence provider, has released its latest research "The Future of Oncology Therapeutics-Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis." The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global oncology therapeutics market. The report analyzes the markets for oncology therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope
The scope of this report includes:
-Annualized market data for the oncology therapeutics market from 2000 to 2008, forecast forward to 2015
-Analysis of the leading therapeutic segments including lung cancer, breast cancer, prostate cancer, colorectal cancer and Non-Hodgkin's Lymphoma.
-Analysis of the oncology diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
-Market characterization of the oncology therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
-Key drivers and barriers that have a significant impact on the market
-Coverage of pipeline molecules in various phases of drug development
-Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Novartis AG, Sanofi-aventis, Amgen, AstraZeneca, Merck & Co, Pfizer Inc, Celgene Corporation, Bristol-Myers Squibb and Eli Lilly
-Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global oncology therapeutics market

Reasons to buy
The report will enhance your decision making capability. It will allow you to
-Align product portfolio to the markets with high growth potential
-Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
-Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
-Develop key strategic initiatives by understanding key focus areas of leading companies
-Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Table of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 8
1.2 List of Figures 10
2 Global Oncology Therapeutics Market: Introduction 13
2.1 GBI Research Report Guidance 14
3 Global Oncology Therapeutics Market: Cancer Epidemiology 15
4 Global Oncology Therapeutics Market: Market Overview 16
4.1 Introduction 16
4.2 Revenue Forecasts for the Global Oncology Therapeutics Market 18
4.2.1 Sales Value 18
4.2.2 Sales Volume 19
4.2.3 Drug Prices 20
4.2.4 Treatment Usage Patterns 21
4.3 Generics in Oncology Therapeutics Market 25
4.4 Oncology therapeutics market Drivers 26
4.4.1 Steady Increase in the Ageing Population 26
4.4.2 New Innovative Products in the Pipeline 27
4.4.3 Rapid Uptake of Targeted Therapies in Key Cancer Indications 27
4.5 Oncology Therapeutics Market Restraints 27
4.5.1 The US Cancer Incidence Moving Towards a Decelerating Growth Rate 27
4.5.2 Patent Expirations and Entry of Generics Pose as a Severe Threat for Primary Manufacturers 28
4.5.3 Restrictive Pricing and Reimbursement Policies Causing Serious Problems in the Oncology Therapeutics Market Growth 29
4.5.4 More Than 80 Molecules to be Launched Over the Next Seven years-Leading to More Competition 30
5 Global Oncology Therapeutics Market: Pricing and Reimbursement 31
5.1 Average Cost of Drug Treatment 31
5.2 The US 33
5.2.1 Pricing 33
5.2.2 Medicare Reimbursement on Cancer Drugs 33
5.3 Europe 34
5.3.1 Pricing and Reimbursement-Country Analysis 36
6 Global Oncology Therapeutics Market: Geographical Landscape 41
6.1 Geographic Break-up 41
6.2 The US 42
6.2.1 Sales Value 42
6.2.2 Sales Volume 43
6.2.3 Drug Prices 44
6.2.4 Treatment Usage Patterns 45
6.3 Top Five European Countries 49
6.3.1 Sales Value 49
6.3.2 Sales Volume 51
6.3.3 Drug Prices 51
6.3.4 Treatment Usage Patterns 53
6.4 Japan 57
6.4.1 Sales Value 57
6.4.2 Sales Volume 58
6.4.3 Drug Prices 59
6.4.4 Treatment Usage Patterns 60
7 Global Oncology Therapeutics Market: Therapeutic Landscape 65
7.1 Breast Cancer Therapeutics Market 65
7.1.1 Introduction 65
7.1.2 Sales Value 67
7.1.3 Sales Volume 68
7.1.4 Drug Prices 69
7.1.5 Treatment Usage Patterns 70
7.2 Non-Hodgkin's Lymphoma Therapeutics Market 75
7.2.1 Introduction 75
7.2.2 Sales Value 76
7.2.3 Sales Volume 78
7.2.4 Drug Prices 78
7.2.5 Treatment Usage Patterns 79
7.3 Colorectal Cancer Therapeutics Market 83
7.3.1 Introduction 83
7.3.2 Sales Value 87
7.3.3 Sales Volume 88
7.3.4 Drug Prices 89
7.3.5 Treatment Usage Patterns 90
7.4 Prostate Cancer Therapeutics Market 94
7.4.1 Introduction 94
7.4.2 Sales Value 96
7.4.3 Sales Volume 97
7.4.4 Drug Prices 98
7.4.5 Treatment Usage Patterns 99
7.5 Lung Cancer Therapeutics Market 103
7.5.1 Introduction 103
7.5.2 Sales Value 107
7.5.3 Sales Volume 108
7.5.4 Drug Prices 109
7.5.5 Treatment Usage Patterns 109
8 Global Oncology Therapeutics Market: Pipeline Analysis 115
8.1 Introduction 115
8.1.1 R&D Strategies 116
8.2 R&D Trends 117
8.2.1 Discovery of Unknown Mutations that Play Key Role in Cancers 117
8.2.2 Pairing Therapeutics and Diagnostics 118
8.3 Profiles of Key Late-Stage Drugs 119
8.3.1 Angiogenesis and Multi-Targeted Kinase Inhibitors 119
8.3.2 Hsp90 Inhibitors 121
8.3.3 Insulin-like Growth Factor Receptor Inhibitors 122
8.3.4 Hedgehog Inhibitors 124
8.3.5 Immuno-conjugates 124
8.4 Insights into Most Promising Drugs 125
8.4.1 Provenge 125
8.4.2 Denosumab 127
8.4.3 Tasigna 129
8.4.4 Aflibercept 130
8.4.5 Tykerb 131
9 Global Oncology Therapeutics Market: Competitive Landscape 134
9.1 Evolving competitive landscape 134
9.1.1 Major players 135
9.1.2 Key areas focused for R&D 135
9.1.3 Challenges faced by brands in marketing the oncology products 136
9.2 Market Share Analysis 138
9.2.1 Rituxan, Avastin, Revlimid and Herceptin are expected to lead the market through 2015 139
9.3 Roche/Genentech 141
9.3.1 Key Oncology Drugs 142
9.3.2 Key Indications of Interest 145
9.3.3 Pipeline Analysis 146
9.3.4 Key Strategies 148
9.4 Novartis 148
9.4.1 Key Oncology Drugs 149
9.4.2 Key Indications of Interest 152
9.4.3 Pipeline Analysis 152
9.4.4 Key Strategies 153
9.5 Sanofi-Aventis 155
9.5.1 Key Oncology Drugs 156
9.5.2 Key Indications of Interest 157
9.5.3 Pipeline Analysis 158
9.5.4 Key Strategies 159
9.6 Amgen 160
9.6.1 Key Oncology Drugs 161
9.6.2 Key of Indications of Interests 163
9.6.3 Pipeline Analysis 163
9.6.4 Key Strategies 165
9.7 Astra Zeneca 165
9.7.1 Key Oncology Drugs 166
9.7.2 Key Indications of Interests 167
9.7.3 Pipeline Analysis 168
9.7.4 Key Strategies 169
10 . Global Oncology Therapeutics Market: M&A Landscape 170
10.1 Overview 170
10.1.1 Pfizer Acquires Wyeth 170
10.1.2 Roche Acquires Genentech 170
10.1.3 Takeda Pharmaceutical Acquires IDM Pharma 171
10.1.4 EUS Pharma Acquires Cytogen Corporation 171
10.1.5 GlaxoSmithKline Acquires Sirtris Pharmaceuticals 171
10.1.6 GlaxoSmithKline Acquires Bristol-Myers Squibb (Egyptian unit) 171
10.1.7 Pfizer Enters into an Agreement with Aurobindo Pharma and Claris Life Sciences 171
10.1.8 Teva Pharmaceuticals Acquires Barr 171
10.1.9 Sanofi-Aventis Acquires Medley 171
10.2 R&D Licensing Agreements 171
10.2.1 Deals by Phase 172
10.2.2 Deals by Geography 172
10.2.3 Deals by Licensing Type 173
10.2.4 Deals by Value ($) 174
10.2.5 Preclinical 174
10.2.6 Phase I 176
10.2.7 Phase II 177
10.2.8 Phase III 178
10.2.9 Approved 180
11 . Global Oncology Therapeutics Market: Appendix 182
11.1 Research Methodology 182
11.2 Geographical Scope 182
11.3 Coverage 182
11.4 Secondary Research 183
11.5 Primary Research 183
11.6 Models 183
11.7 Forecasts 184
11.8 Expert Panel Validation 184
11.9 Contact Us 184
11.10 Disclaimer 184

List of Tables
1.1 List of Tables
Table 1: Oncology Therapeutics Market, Global, Revenue Forecasts ($ m), 2000-2008 17
Table 2: Oncology Therapeutics Market, Global, Revenue Forecasts ($ m), 2008-2015 17
Table 3: Oncology Therapeutics Market, Global, Sales Volume (million), 2000-2008 18
Table 4: Oncology Therapeutics Market, Global, Sales Volume (million), 2009-15 18
Table 5: Oncology Therapeutics Market, Global, Average Cost per Dose ($), 2000-2008 19
Table 6: Oncology Therapeutics Market, Global, Average Cost per Dose ($), 2008-2015 19
Table 7: Oncology Therapeutics Market, Global, Treatment Usage Patterns, Historic 2000-2008 20
Table 8: Oncology Therapeutics Market, Global, Treatment Usage Patterns, Forecasts 2008-2015 21
Table 9: Oncology Therapeutics Market, Global, Generics Sales Forecast, 2008-2015 25
Table 10: Oncology Therapeutics Market, The US, Major Drug Patent Expirations, 2009-19 28
Table 11: Oncology Therapeutics, Global, Annual Cost of Therapy ($), 2000-2008 31
Table 12: Oncology Therapeutics, Global, Annual Cost of Therapy ($), 2008-2015 31
Table 13: Direct Medical Costs for Cancer Care in Select European Countries-2008 33
Table 14: Reimbursement Rates based on Pharamco-economic Evaluation-2008 37
Table 15: Italy Reimbursement Coverage System-2008 38
Table 16: Spain Pharmaceutical Pricing System-2008 39
Table 17: Italy Reimbursement Coverage System-2008 39
Table 18: Oncology Therapeutics Market, Global, Revenue Break-up by Geography ($ m), 2000-2008 40
Table 19: Oncology Therapeutics Market, Global, Revenue Break-up by Geography ($ m), 2008-2015 41
Table 20: Oncology Therapeutics Market, The US, Revenue Forecasts ($ m), 2000-2008 42
Table 21: Oncology Therapeutics Market, The US, Revenue Forecasts ($ m), 2008-2015 42
Table 22: Oncology Therapeutics Market, The US, Volume Forecasts (million), 2000-2008 43
Table 23: Oncology Therapeutics Market, The US, Volume Forecasts (million), 2008-2015 43
Table 24: Oncology Therapeutics Market, The US, Average Cost per Dose ($), 2000-2008 44
Table 25: Oncology Therapeutics Market, The US, Average Cost per Dose ($), 2008-2015 44
Table 26: Oncology Therapeutics Market, The US, Treatment Usage Patterns, 2000-2008 45
Table 27: Oncology Therapeutics Market, The US, Treatment Usage Patterns, 2008-2015 45
Table 28: Oncology Therapeutics Market, Europe, Revenue Forecasts ($ m), 2000-2008 49
Table 29: Oncology Therapeutics Market, Europe, Revenue Forecasts ($ m), 2008-2015 49
Table 30: Oncology Therapeutics Market, Europe, Volume Forecasts (million), 2000-2008 50
Table 31: Oncology Therapeutics Market, Europe, Volume Forecasts (million), 2008-2015 50
Table 32: Oncology Therapeutics Market, Europe, Average Cost per Dose ($), 2000-2008 51
Table 33: Oncology Therapeutics Market, Europe, Average Cost per Dose ($), 2008-2015 52
Table 34: Oncology Therapeutics Market, Europe, Treatment Usage Patterns, 2000-2008 52
Table 35: Oncology Therapeutics Market, Europe, Treatment Usage Patterns, 2008-2015 53
Table 36: Oncology Therapeutics Market, Japan, Revenue ($ bn), 2000-2008 57
Table 37: Oncology Therapeutics Market, Japan, Revenue ($ bn), 2008-2015 57
Table 38: Oncology Therapeutics Market, Japan, Volume Forecasts (million), 2000-2008 58
Table 39: Oncology Therapeutics Market, Japan, Volume Forecasts (million), 2008-2015 58
Table 40: Oncology Therapeutics Market, Japan, Average Cost per Dose ($), 2000-2008 59
Table 41: Oncology Therapeutics Market, Japan, Average Cost per Dose ($), 2009-15 59
Table 42: Oncology Therapeutics Market, Japan, Treatment Usage Patterns, 2000-2008 60
Table 43: Oncology Therapeutics Market, Japan, Treatment Usage Patterns, 2008-2015 60
Table 44: Breast Cancer Therapeutics Market, Global, Cancer Categorized by Disease Stage 65
Table 45: Breast Cancer Therapeutics Market, Global, Revenue ($ bn), 2000-2008 67
Table 46: Breast Cancer Therapeutics Market, Global, Revenue ($ bn), 2008-2015 67
Table 47: Breast Cancer Therapeutics Market, Global, Volume (million), 2000-2008 68
Table 48: Breast Cancer Therapeutics Market, Global, Volume (million), 2008-2015 68
Table 49: Breast Cancer Therapeutics Market, Global, Average Cost per Dose ($),  2000-2008 69
Table 50: Breast Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2008-2015 69
Table 51: Breast Cancer Therapeutics Market, Global, Usage Patterns, 2000-2008 70
Table 52: Breast Cancer Therapeutics Market, Global, Usage Patterns, 2008-2015 71
Table 53: Non-Hodgkin's Lymphoma Therapeutics Market, Global, Cancer Categorized by Disease Stage 74
Table 54: Non-Hodgkin's Lymphoma Therapeutics Market, Global, Revenue ($ bn),  2000-2008 76
Table 55: Non-Hodgkin's Lymphoma Therapeutics Market, Global, Revenue ($ bn),  2008-2015 76
Table 56: Non-Hodgkin's Lymphoma Therapeutics Market, Global, Volume (million),  2000-2008 77
Table 57: Non-Hodgkin's Lymphoma Therapeutics Market, Global, Volume (million),  2008-2015 77
Table 58: Non-Hodgkin's Lymphoma Therapeutics Market, Global, Average Cost per Dose ($), 2000-2008 78
Table 59: Non-Hodgkin's Lymphoma Therapeutics Market, Global, Average Cost per Dose ($), 2008-2015 78
Table 60: Non-Hodgkin's Lymphoma Therapeutics Market, Global, Usage Patterns,  2000-2008 79
Table 61: Non-Hodgkin's Lymphoma Therapeutics Market, Global, Usage Patterns,  2008-2015 80
Table 62: Colorectal Cancer Therapeutics Market, Global, Cancer Categorized by Disease Stage 84
Table 63: Colorectal Cancer Therapeutics Market, Global, Revenue ($ bn), 2000-2008 86
Table 64: Colorectal Cancer Therapeutics Market, Global, Revenue ($ bn), 2008-2015 86
Table 65: Colorectal Cancer Therapeutics Market, Global, Volume (million), 2000-2008 87
Table 66: Colorectal Cancer Therapeutics Market, Global, Volume (million), 2008-2015 87
Table 67: Colorectal Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2000-2008 88
Table 68: Colorectal Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2008-2015 88
Table 69: Colorectal Cancer Therapeutics Market, Global, Usage Patterns, 2000-2008 90
Table 70: Colorectal Cancer Therapeutics Market, Global, Usage Patterns, 2008-2015 90
Table 71: Prostate Cancer Therapeutics Market, Global, Cancer Categorized by Disease Stage 94
Table 72: Prostate Cancer Therapeutics Market, Global, Revenue ($ bn), 2000-2008 96
Table 73: Prostate Cancer Therapeutics Market, Global, Revenue ($ bn), 2008-2015 96
Table 74: Prostate Cancer Therapeutics Market, Global, Volume (million), 2000-2008 96
Table 75: Prostate Cancer Therapeutics Market, Global, Volume (million), 2008-2015 97
Table 76: Prostate Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2000-2008 97
Table 77: Prostate Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2008-2015 98
Table 78: Prostate Cancer Therapeutics Market, Global, Usage Patterns, 2000-2008 99
Table 79: Prostate Cancer Therapeutics Market, Global, Usage Patterns, 2008-2015 99
Table 80: Lung Cancer Therapeutics Market, Global, Cancer Categorized by Disease Stage 103
Table 81: Lung Cancer Therapeutics Market, Global, NSCLC Treatment by Stage of the Disease 105
Table 82: Lung Cancer Therapeutics Market, Global, Revenue ($ bn), 2000-2008 106
Table 83: Lung Cancer Therapeutics Market, Global, Revenue ($ bn), 2008-2015 107
Table 84: Lung Cancer Therapeutics Market, Global, Volume (million), 2000-2008 107
Table 85: Lung Cancer Therapeutics Market, Global, Volume (million), 2008-2015 107
Table 86: Lung Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2000-2008 108
Table 87: Lung Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2008-2015 108
Table 88: Lung Cancer Therapeutics Market, Global, Usage Patterns, 2000-2008 110
Table 89: Lung Cancer Therapeutics Market, Global, Usage Patterns, 2008-2015 110
Table 90: Oncology Therapeutics Market, Global, Top 10 Brands' Sales ($ m), 2006-2008 139
Table 91: Oncology Therapeutics Market, Global, Roche/Genentech Sales, 2006-2015 141
Table 92: Oncology Therapeutics Market, Global, Novartis, Sales ($ m), 2006-2015 148
Table 93: Oncology Therapeutics Market, Global, Sanofi-Aventis, Sales ($ m), 2006-15 155
Table 94: Oncology Therapeutics Market, Global, Amgen, Sales ($ m), 2006-2015 160
Table 95: Oncology Therapeutics Market, Global, AstraZeneca, Sales ($ m), 2006-2015 165
Table 96: Oncology Therapeutics Market, Global, Licensing Agreements for Drugs in the Preclinical Stage, 2008-09 174
Table 97: Oncology Therapeutics Market, Global,  Licensing Agreements for Drugs in the Phase I, 2008-09 175
Table 98: Oncology Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II, 2008-09 176
Table 99: Oncology Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III, 2008-09 178
Table 100: Oncology Therapeutics Market, Global, Licensing Agreements for Approved Drugs, 2008-09 179

List of Figures
1.2 List of Figures
Figure 1: MAbs Market, Global, Major Factors Influencing the Global MAbs Market, 2008 14
Figure 2:  MAbs Market, Global, MAbs Treatment Potential, 2000-15 15
Figure 3:  MAbs Market, Global, Annual Cost of Therapy ($), 2000-2015 16
Figure 4:  MAbs Market, Global, MAbs Market Potential ($ bn), 2000-2015 17
Figure 5:  MAbs Market, Global, Market Segmentation by Disease, 2008 and 2015 19
Figure 6:  MAbs Market, Global, MAbs Actual Treatment Population, 2000-2015 20
Figure 7:  MAbs Market, Global, Actual Sales ($ bn), 2000-2015 21
Figure 8:  MAbs Market, Global, Actual Sales Segmentation ($ bn), 2008 and 2015 22
Figure 9:  MAbs Market, Global, Actual Sales Segmentation ($ bn), 2000-2015 23
Figure 10: MAbs Market, Global, Treatment Population Trends, 2000-2015 24
Figure 11: MAbs Market, Global, MAbs Segmented by Origin, 1992-2009 25
Figure 12: MAbs Market, Global, Market Share of Key Indications, 2008 29
Figure 13: MAbs Market, Global, HER2+ Breast Cancer, Prescription Population, 2000-2015 31
Figure 14: MAbs Market, Global, HER2+ Breast Cancer, Annual Cost of Therapy ($), 2000-2015   32
Figure 15: MAbs Market, Global, HER2+ Breast Cancer, Market Potential ($ bn), 2000-2015 33
Figure 16: MAbs Market, Global, Bone Metastasis and Bone Loss, Prescription Population,  2009-2015 36
Figure 17: MAbs Market, Global, Bone Metastasis and Bone Loss, Annual Cost of Therapy ($), 2009-2015 37
Figure 18: MAbs Market, Global, Bone Metastasis and Bone Loss, Market Potential  ($ bn), 2009-2015 38
Figure 19: MAbs Market, Global, Multiple Sclerosis, Diseased Population, 2008 39
Figure 20: MAbs Market, Global, RRMS, Prescription Population, 2000-2015 40
Figure 21: MAbs Market, Global, RRMS, Annual Cost of Therapy ($), 2000-2015 41
Figure 22: MAbs Market, Global, RRMS, Market Potential ($ bn), 2000-2015 42
Figure 23: MAbs Market, Global, Metastatic NSCLC, Prescription Population, 2000-2015 45
Figure 24: MAbs Market, Global, Metastatic NSCLC, Annual Cost of Therapy ($),  2000-2015 46
Figure 25: MAbs Market, Global, Metastatic NSCLC, Market Potential ($ bn), 2000-2015 47
Figure 26: MAbs Market, Global, Rheumatoid Arthritis, Prescription Population,  2000-2015 50
Figure 27: MAbs Market, Global, Rheumatoid Arthritis, Annual Cost of Therapy ($), 2000-2015   51
Figure 28: MAbs Market, Global, Rheumatoid Arthritis, Market Potential ($ bn), 2000-2015 52
Figure 29: MAbs Market, Global, Pipeline Segmentation by Disease, 2009 53
Figure 30: MAbs Market, Global, Oncology Pipeline, 2009 56
Figure 31: MAbs Market, Global, Autoimmune Diseases Pipeline, 2009 66
Figure 32: MAbs Market, Global, Respiratory Diseases Pipeline by Phase of Development, 2009 74
Figure 33: MAbs Market, Global, Infectious Diseases Pipeline by Phase of Development, 2009   76
Figure 34: MAbs Market, Global, Organ Transplantation Pipeline by Phase of Development, 2009 78
Figure 35: MAbs Market, Global, Cardiovascular Pipeline by Phase of Development, 2009 80
Figure 36: MAbs Market, Global, Other New Indications in Pipeline, 2009 82
Figure 37: MAbs Market, Global Major M&A Deals, 2008-2009 86
Figure 38: MAbs Market, Global, Major Licensing Agreements by Phase, 2008-2009 87
Figure 39: MAbs Market, Global, Major Licensing Agreements By Geography, 2008-2009 88
Figure 40: MAbs Market, Global, Major Licensing Agreements By Deal Value, 2008-2009 88
Figure 41: MAbs Market, Global, Top Three Companies, 2008 94
Figure 42: MAbs Market, Global, Top 5 Companies Sales Trend, 2006-2008 95
Figure 43: MAbs Market, Global, Key Target Therapies Launched, 1997-2009 96
Figure 44: MAbs Market, Global, Company Market Share Analysis, 2008 96
Figure 45: MAbs Market, Global, Company Benchmarking Analysis, 2008 97
Figure 46: MAbs Market, Global, Top 10 MAbs, 2006-2008 98
Figure 47: MAbs Market, Global, Roche/Genentech Revenue Segmentation, 2008 99
Figure 48: MAbs Market, Global, Roche/Genentech Revenue ($ m), 2006-2015 100
Figure 49: MAbs Market, Global, Roche/Genentech R&D Pipeline by Therapeutic Area, November 2009 103
Figure 50: MAbs Market, Global, Roche/Genentech Pipeline Analysis by Phase, November 2009 104
Figure 51: MAbs Market, Global, Abbott Revenue Segmentation, 2008 104
Figure 52: MAbs Market, Global, Abbott Revenue ($ m), 2006-2015 105
Figure 53: MAbs Market, Global, Abbott Pipeline Analysis by Phase, November 2009 106
Figure 54: MAbs Market, Global, Johnson & Johnson Revenue ($ m), 2006-2015 107
Figure 55: MAbs Market, Global, Johnson & Johnson R&D Pipeline by Therapeutic Area,  November 2009 108
Figure 56: MAbs Market, Global, Johnson & Johnson Pipeline Analysis by Phase, November 2009 109
Figure 57: MAbs Market, Global, Biogen Idec Revenue Segmentation, 2008 109
Figure 58: MAbs Market, Global, Biogen Idec Revenue ($ m), 2006-2015 110
Figure 59: MAbs Market, Global, Biogen Idec R&D Pipeline by Therapeutic Area, November  2009 111
Figure 60: MAbs Market, Global, Biogen Idec Pipeline Analysis by Phase, November 2009 112
Figure 61: MAbs Market, Global, Merck/Schering Plough Revenues ($ m), 2006-2015 113
Figure 62: MAbs Market, Global, Merck/Schering-Plough R&D Pipeline by Therapeutic Area, November 2009 114
Figure 63: MAbs Market, Global, Merck/Schering-Plough Pipeline Analysis by Phase, November  2009 114
Figure 64: MAbs Market, Global, AstraZeneca Revenues ($ m), 2006-2015 115
Figure 65: MAbs Market, Global, AstraZeneca R&D Pipeline by Therapeutic Area, November 2009 116
Figure 66: MAbs Market, Global, AstraZeneca Pipeline Analysis by Phase, November 2009 117
Figure 67: MAbs Market, Global, Bristol-Myers Squibb Revenues ($ m), 2006-2015 118
Figure 68: MAbs Market, Global, Bristol-Myers Squibb R&D Pipeline by Phase, November 2009 119
Figure 69: MAbs Market, Global, Elan Revenues ($ m), 2006-2015 120
Figure 70: MAbs Market, Global, Elan R&D Pipeline by Therapeutic Area, November 2009 121
Figure 71: MAbs Market, Global, Elan Pipeline Analysis by Phase, November 2009 121
Figure 72: MAbs Market, Global, Eli Lilly, Revenues ($ m), 2006-2015 122
Figure 73: MAbs Market, Global, Eli Lilly R&D Pipeline by Therapeutic Area, November 2009 123
Figure 74: MAbs Market, Global, Eli Lilly Pipeline Analysis by Phase, November 2009 124
Figure 75: MAbs Market, Global, Amgen Revenues ($ m), 2006-2015 125
Figure 76: MAbs Market, Global, Amgen R&D Pipeline by Therapeutic Area, November 2009 127
Figure 77: MAbs Market, Global, Amgen Pipeline Analysis by Phase, November 2009 127
Figure 78: GBI Research Methodology 128
Figure 79: GBI Research Market Forecasting Model 131